Pharmosa Biopharm (ROCO:6875) ROCE %: -25.95% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
11 GF Score
Price NT$35.55
! 1 Warning Sign
View Full Analysis

What is Pharmosa Biopharm ROCE %?

Pharmosa Biopharm ROCO:6875 +0.14% 11 ROCE % is -25.95% as of Dec. 2025. GuruFocus rates ROCO:6875 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmosa Biopharm's annualized ROCE % for the quarter that ended in Dec. 2025 was -25.95%.

Pharmosa Biopharm  (ROCO:6875) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmosa Biopharm ROCE % Related Terms

Pharmosa Biopharm ROCE % Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm ROCE % Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -51.19 -40.13 1.12 -9.94 -20.65

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 -18.49 -28.36 -10.15 -25.95
ROCO:6875
11GF Score
Pharmosa Biopharm Inc ROCO:6875
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm ROCE % Calculation

Pharmosa Biopharm's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-381.749/( ( (2163.602 - 116.131) + (1748.515 - 99.469) )/ 2 )
=-381.749/( (2047.471+1649.046)/ 2 )
=-381.749/1848.2585
=-20.65 %

Pharmosa Biopharm's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=-442.736/( ( (1857.51 - 94.775) + (1748.515 - 99.469) )/ 2 )
=-442.736/( ( 1762.735 + 1649.046 )/ 2 )
=-442.736/1705.8905
=-25.95 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -25.95% mean?
Pharmosa Biopharm (ROCO:6875) has a ROCE % of -25.95% as of Dec. 2025.
Is Pharmosa Biopharm's ROCE % too high?
Pharmosa Biopharm's current ROCE % is -25.95%. Overall, Pharmosa Biopharm has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's ROCE % compare to VRTX and REGN?
Pharmosa Biopharm's ROCE % of -25.95% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pharmosa Biopharm's current ROCE % is -25.95%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current ROCE % of -25.95%. The current ROCE % is -25.95%. Pharmosa Biopharm's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current ROCE % is -25.95% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
11GF Score

Get the complete analysis for ROCO:6875

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.55
Price